Estimaciones de analistas de Wall Street para Omeros Corporation (OMER): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 1 |
| Compra | 10 |
| Mantener | 6 |
| Venta | 2 |
| Venta fuerte | 0 |
| Analistas totales | 19 |
| Calificación media (1-5) | 0.53 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.05 | ||
| 2026-08-13 | $0.15 | $-0.27 | +155.9% |
| 2026-05-13 | $-0.24 | $-0.40 | +40.0% |
| 2026-03-31 | $3.14 | $-0.55 | +670.9% |
| 2025-11-13 | $-0.47 | $-0.58 | +19.0% |
| 2025-08-14 | $-0.43 | $-0.55 | +21.8% |
| 2025-05-15 | $-0.58 | $-0.57 | -2.5% |
| 2025-03-31 | $-0.54 | $-0.78 | +30.4% |
Ratios de valoración
| Ratio P/E | 8.04 |
| Precio / Valor contable | -21.57 |
| EV / EBITDA | 9.73 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $41.6M | $64.8M | $29.9M | $111.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $1.4M | $1.1M | $512000 | $2.7M | $1.6M | $1.4M | 0 | 0 | 0 | 0 |
| Beneficio Bruto | $40.2M | $63.7M | $29.4M | $109.2M | -$1.6M | -$1.4M | 0 | 0 | 0 | 0 |
| I+D | $50.7M | $55.6M | $89.9M | $109.7M | $107.6M | $118.8M | $112.7M | $114.9M | $119.5M | $81.3M |
| Generales y Administrativos | $43.8M | $52.0M | $51.7M | $62.8M | $47.7M | $53.5M | $50.7M | $49.7M | $49.7M | $41.5M |
| Gastos Operativos | $94.5M | $107.6M | $141.6M | $172.5M | $155.3M | $172.2M | $163.4M | $164.5M | $169.3M | $122.8M |
| Beneficio Operativo | -$54.3M | -$43.9M | -$112.2M | -$63.4M | -$156.9M | -$173.6M | -$163.4M | -$164.5M | -$169.3M | -$122.8M |
| EBITDA | -$58.6M | -$41.9M | -$122.5M | -$60.0M | -$168.0M | -$170.5M | -$158.4M | -$143.2M | -$157.0M | -$1.8M |
| Gastos por Intereses | $7.8M | $11.0M | $16.3M | $22.7M | $26.8M | $19.7M | $22.7M | $30.8M | $24.7M | 0 |
| Beneficio Antes de Impuestos | -$66.7M | -$53.5M | -$139.7M | -$84.5M | -$196.4M | -$191.5M | -$182.0M | -$174.9M | -$182.6M | -$2.8M |
| Impuestos | 0 | 0 | -$12.9M | 0 | -$23.3M | 0 | 0 | 0 | 0 | $2.0M |
| Beneficio Neto | -$66.7M | -$53.5M | -$126.8M | -$84.5M | -$138.1M | -$111.4M | $47.4M | -$117.8M | -$156.8M | -$3.4M |
| BPA | $-1.65 | $-1.17 | $-2.61 | $-2.16 | $-2.41 | $-1.79 | $0.46 | $-1.88 | $-2.70 | $-0.05 |
| BPA Diluido | $-1.65 | $-1.17 | $-2.61 | $-2.16 | $-2.41 | $-1.79 | $0.46 | $-1.88 | $-2.70 | $-0.05 |
| Acciones en Circulación (Diluidas) | $40.4M | $45.5M | $48.6M | $49.5M | $57.2M | $62.3M | $62.7M | $62.7M | $58.2M | $63.5M |
Precio
| Precio | $17.34 |
| Capitalización | $1.3B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ADCT · BCYC · FDMT · FULC · GOSS · KALV · LXRX
Explorar sector: Healthcare · Biotechnology
Más secciones de OMER: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones